GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Argenica Therapeutics AGN.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.11

—

Close of 9 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2025

Revenue

A$512,800

FY2020FY2025

Net income

−A$7.2m

FY2020FY2025

Free cash flow

—

FY2020FY2025

Shareholders' equity

A$7.2m

FY2020FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
RevenueA$512,800A$192,100A$61,000A$2,500A$200A$300
Research and developmentA$8.1mA$6.0mA$4.3mA$2.5mA$416,100A$333,000
Operating income−A$10.2m−A$8.1m−A$6.5m−A$4.3m−A$1.1m−A$383,400
Net income−A$7.2m−A$5.5m−A$4.8m−A$4.1m−A$1.0m−A$383,400
Diluted earnings per share-0.06-0.05-0.06-0.06-0.01-0.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Total assetsA$11.0mA$16.4mA$9.5mA$9.0mA$7.3mA$377,700
Cash and short-term investmentsA$10.6mA$15.9mA$9.3mA$8.9mA$7.1mA$342,000
Total liabilitiesA$3.8mA$2.4mA$1.9mA$735,900A$425,700A$359,300
Shareholders' equityA$7.2mA$14.0mA$7.7mA$8.3mA$6.8mA$18,400
Shares outstanding128m104m88m74m73m73m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations—−A$5.1m−A$3.3m−A$3.4m−A$1.0m−A$58,800
Free cash flow—−A$5.1m−A$3.3m−A$3.4m−A$1.0m−A$58,800

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022
RevenueA$93,400A$239,300A$273,500A$140,300A$51,800A$40,400A$20,600A$1,200
Operating income−A$3.8m−A$9.2m−A$1.2m−A$4.3m−A$3.8m−A$3.6m−A$2.9m−A$2.3m
Net income−A$3.8m−A$6.0m−A$1.2m−A$4.1m−A$1.4m−A$3.3m−A$1.6m−A$2.3m
Diluted earnings per share-0.03-0.05-0.01-0.04-0.01-0.04-0.02-0.03
Cash from operations—−A$4.0m−A$1.0m−A$3.0m———−A$1.0m
Total assetsA$5.2mA$11.0mA$15.4mA$16.4mA$8.6mA$9.5mA$8.3mA$9.0m
Cash and short-term investmentsA$5.0mA$10.6mA$15.1mA$15.9mA$8.4mA$9.3mA$8.1mA$8.9m
Shareholders' equityA$3.4mA$7.2mA$13.2mA$14.0mA$6.6mA$7.7mA$6.9mA$8.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue489.8%343.2%—
Operating income33.6%92.8%—
Net income20.6%79.6%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-2594.2%-3782.4%-3970.4%—
Net margin-1794.6%-2805.3%-2987.2%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-5.3-5.2-4.0-3.5-25.8
Price to sales73.4147.7317.9——

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.